Idea Di Pharmaceutical 3D011 has been approved for clinical use in advanced solid tumors

Source: Pharmaceutical Mission Hills On January 29, 3D Pharmaceuticals announced that its application for clinical trial of 3D011, a class of innovative class 1 drug developed independently, had been approved by the Drug Review Center (CDE) of the State Drug Administration of China for advanced solid tumors.
3D011 is the company's first innovative drug to be developed in-void, according to a news release from Mindy Pharmaceuticals.
3D011 for this approved clinical trial is the first innovative drug developed by Wedi Pharmaceuticals.
press release, research and development of 3D011 began at the end of 2016.
3D011's starting compound is an oral high-efficiency anti-cancer drug, the mother drug on the related kinase has a better inhibitory effect, clinical data have fully proved that it has a better anti-tumor efficacy, but the disadvantage is that there is a higher systemic toxicity.
, the Research and Development Team of Mindy Pharmaceuticals decided to improve its pharmacological dynamics through pre-drug design, thereby reducing its systemic toxicity.
after a round of design, optimization, synthesis, the research and development team has overcome one difficulty after another, and finally completed the production of clinical samples of API.
3D011 showed that 3D011 significantly inhibited tumor growth.
safety pharmacological studies, 3D011 did not inhibit the heERG channel.
there were no significant abnormalities in the central nervous system, the cardiovascular system and respiratory function of dogs.
drug-related toxicological reactions were not found in toxicology studies in mice and dogs.
(content is reduced) and pay attention to the Public Number of WeChat